Flortaucipir tau PET findings from former professional and college American football players in the DIAGNOSE CTE research project.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
Mar 2024
Historique:
revised: 27 10 2023
received: 25 06 2023
accepted: 20 11 2023
medline: 18 3 2024
pubmed: 22 12 2023
entrez: 22 12 2023
Statut: ppublish

Résumé

Tau is a key pathology in chronic traumatic encephalopathy (CTE). Here, we report our findings in tau positron emission tomography (PET) measurements from the DIAGNOSE CTE Research Project. We compare flortaucipir PET measures from 104 former professional players (PRO), 58 former college football players (COL), and 56 same-age men without exposure to repetitive head impacts (RHI) or traumatic brain injury (unexposed [UE]); characterize their associations with RHI exposure; and compare players who did or did not meet diagnostic criteria for traumatic encephalopathy syndrome (TES). Significantly elevated flortaucipir uptake was observed in former football players (PRO+COL) in prespecified regions (p < 0.05). Association between regional flortaucipir uptake and estimated cumulative head impact exposure was only observed in the superior frontal region in former players over 60 years old. Flortaucipir PET was not able to differentiate TES groups. Additional studies are needed to further understand tau pathology in CTE and other individuals with a history of RHI.

Identifiants

pubmed: 38134231
doi: 10.1002/alz.13602
doi:

Substances chimiques

7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole J09QS3Z3WB
tau Proteins 0
Carbolines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1827-1838

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM109025
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG072978
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS093334
Pays : United States

Informations de copyright

© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Références

McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol. 2009;68:709-735.
Goldstein LE, Fisher AM, Tagge CA, et al. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med. 2012;4:134ra60.
McKee AC, Cairns NJ, Dickson DW, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131:75-86.
McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136:43-64.
Bieniek KF, Cairns NJ, Crary JF, et al. The second NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2021;80:210-219.
Katz DI, Bernick C, Dodick DW, et al. National institute of neurological disorders and stroke consensus diagnostic criteria for traumatic encephalopathy syndrome. Neurology. 2021;96:848-863.
Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of american football. JAMA. 2017;318:360-370.
McKee AC, Gavett BE, Stern RA, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2010;69:918-929.
Stern RA, Daneshvar DH, Baugh CM, et al. Clinical presentation of chronic traumatic encephalopathy. Neurology. 2013;81:1122-1129.
Alosco ML, Mariani ML, Adler CH, et al. Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE research project. Alzheimers Res Ther. 2021;13:136.
Johnson KA, Schultz A, Betensky RA, et al. Tau PET imaging in aging and early Alzheimer's disease. Ann Neurol. 2015;79(1):110-119.
Day GS, Gordon BA, Jackson K, et al. Tau-PET binding distinguishes patients with early-stage posterior cortical atrophy from amnestic Alzheimer disease dementia. Alzheimer Dis Assoc Disord. 2017;31:87-93.
Leuzy A, Pascoal TA, Strandberg O, et al. A multicenter comparison of [(18)F]flortaucipir, [(18)F]RO948, and [(18)F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur J Nucl Med Mol Imaging. 2021;48:2295-2305.
Fleisher AS, Pontecorvo MJ. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77:829-839.
Pontecorvo MJ, Devous MD, Kennedy I, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. Brain. 2019;142:1723-1735.
Soleimani-Meigooni DN, Iaccarino L, La Joie R, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Brain. 2020;143:3477-3494.
Josephs K, Tosakulwong N, Weigand S, et al. Relationship between (18)F-flortaucipir uptake and histologic lesion types in 4-repeat tauopathies. J Nucl Med. 2021;63(6):931-935.
Alosco ML, Cherry JD, Huber BR, et al. Characterizing tau deposition in chronic traumatic encephalopathy (CTE): utility of the McKee CTE staging scheme. Acta Neuropathol. 2020;140:495-512.
Cherry JD, Kim SH, Stein TD, et al. Evolution of neuronal and glial tau isoforms in chronic traumatic encephalopathy. Brain Pathol. 2020;30:913-925.
Cherry JD, Esnault CD, Baucom ZH, et al. Tau isoforms are differentially expressed across the hippocampus in chronic traumatic encephalopathy and Alzheimer's disease. Acta Neuropathol Commun. 2021;9:86.
Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. Nature. 2021;598:359-363.
Falcon B, Zivanov J, Zhang W, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568:420-423.
Stern RA, Adler CH, Chen K, et al. Tau positron-emission tomography in former national football league players. N Engl J Med. 2019;380:1716-1725.
Su Y, D'Angelo GM, Vlassenko AG, et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One. 2013;8:e73377.
Su Y, Blazey TM, Snyder AZ, et al. Partial volume correction in quantitative amyloid imaging. Neuroimage. 2015;107:55-64.
Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage. 2009;46:154-159.
Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data. Data Brief. 2017;15:648-657.
Montenigro PH, Alosco ML, Martin BM, et al. Cumulative head impact exposure predicts later-life depression, apathy, executive dysfunction, and cognitive impairment in former high school and college football players. J Neurotrauma. 2017;34:328-340.
Daneshvar DH, Nair ES, Rasch A, et al. Leveraging American football accelerometer data to quantify associations between repetitive head impacts and chronic traumatic encephalopathy in males. Nat Commun. 2023;14:3470-3483.
Alosco ML, Tripodis Y, Baucom ZH, et al. White matter hyperintensities in former American football players. Alzheimers Dement. 2023;19:1260-1273.
Dhaynaut M, Grashow R, Normandin MD, et al. Tau positron emission tomography and neurocognitive function among former professional American-style football players. J Neurotrauma. 2023;40(15-16):1614-1624.
Priemer DS, Iacono D, Rhodes CH, Olsen CH, Perl DP. Chronic traumatic encephalopathy in the brains of military personnel. N Engl J Med. 2022;386:2169-2177.
Alosco ML, Su Y, Stein TD, et al. Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players. Eur J Nucl Med Mol Imaging. 2023;50:435-452.
Kelley CM, Perez SE, Mufson EJ. Tau pathology in the medial temporal lobe of athletes with chronic traumatic encephalopathy: a chronic effects of neurotrauma consortium study. Acta Neuropathol Commun. 2019;7:207.
Kotari V, Southekal S, Navitsky M, et al. Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression. Alzheimers Res Ther. 2023;15:41.
Krishnadas N, Dore V, Groot C, et al. Mesial temporal tau in amyloid-beta-negative cognitively normal older persons. Alzheimers Res Ther. 2022;14:51.
Qi B, Tan J, Sun Y, et al. Mechanistic insights into the binding of different positron emission tomography tracers to chronic traumatic encephalopathy tau protofibrils. ACS Chem Neurosci. 2023;14:1512-1523.
Varlow C, Vasdev N. Evaluation of tau radiotracers in chronic traumatic encephalopathy. J Nucl Med. 2023;64:460-465.
Varlow C, Knight AC, McQuade P, Vasdev N. Characterization of neuroinflammatory positron emission tomography biomarkers in chronic traumatic encephalopathy. Brain Commun. 2022;4:fcac019.
Protas H, Ghisays V, Goradia DD, et al. Individualized network analysis: a novel approach to investigate tau PET using graph theory in the Alzheimer's disease continuum. Front Neurosci. 2023;17:1089134.
Landau SM, Ward TJ, Murphy A, et al. Quantification of amyloid beta and tau PET without a structural MRI. Alzheimers Dement. 2023;19:444-455.

Auteurs

Yi Su (Y)

Banner Alzheimer's Institute and Arizona Alzheimer's Consortium, Phoenix, Arizona, USA.

Hillary Protas (H)

Banner Alzheimer's Institute and Arizona Alzheimer's Consortium, Phoenix, Arizona, USA.

Ji Luo (J)

Banner Alzheimer's Institute and Arizona Alzheimer's Consortium, Phoenix, Arizona, USA.

Kewei Chen (K)

Banner Alzheimer's Institute and Arizona Alzheimer's Consortium, Phoenix, Arizona, USA.

Michael L Alosco (ML)

Department of Neurology, Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.

Charles H Adler (CH)

Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Laura J Balcer (LJ)

Departments of Neurology, NYU Grossman School of Medicine, New York, New York, USA.
Department of Population Health and Ophthalmology, NYU Grossman School of Medicine, New York, New York, USA.

Charles Bernick (C)

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA.
Department of Neurology, University of Washington, Seattle, Washington, USA.

Rhoda Au (R)

Department of Neurology, Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Framingham Heart Study, Framingham, Massachusetts, USA.
Slone Epidemiology Center; Departments of Anatomy & Neurobiology, Neurology, and Medicine, Department of Epidemiology, Boston University Chobanian & Avedisian School of Medicine; Boston University School of Public Health, Boston, Massachusetts, USA.

Sarah J Banks (SJ)

Departments of Neuroscience and Psychiatry, University of California, San Diego, California, USA.

William B Barr (WB)

Departments of Neurology, NYU Grossman School of Medicine, New York, New York, USA.

Michael J Coleman (MJ)

Departments of Psychiatry and Radiology, Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

David W Dodick (DW)

Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Douglas I Katz (DI)

Department of Neurology, Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Encompass Health Braintree Rehabilitation Hospital, Braintree, Massachusetts, USA.

Kenneth L Marek (KL)

Institute for Neurodegenerative Disorders, Invicro, LLC, New Haven, Connecticut, USA.

Michael D McClean (MD)

Department of Environmental Health, Boston University School of Public Health, Boston, Massachusetts, USA.

Ann C McKee (AC)

Department of Neurology, Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
VA Boston Healthcare System, Boston, Massachusetts, USA.

Jesse Mez (J)

Department of Neurology, Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Framingham Heart Study, Framingham, Massachusetts, USA.

Daniel H Daneshvar (DH)

Department of Physical Medicine & Rehabilitation, Massachusetts General Hospital, Spaulding Rehabilitation Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.

Joseph N Palmisano (JN)

Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Biostatistics and Epidemiology Data Analytics Center (BEDAC), Boston University School of Public Health, Boston, Massachusetts, USA.

Elaine R Peskind (ER)

Department of Psychiatry and Behavioral Sciences, VA Northwest Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System; University of Washington School of Medicine, Seattle, Washington, USA.

Robert W Turner (RW)

Department of Clinical Research & Leadership, The George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USA.

Jennifer V Wethe (JV)

Department of Psychiatry and Psychology, Mayo Clinic School of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Gil Rabinovici (G)

Department of Neurology, University of California San Francisco, San Francisco, California, USA.

Keith Johnson (K)

Gordon Center for Medical Imaging, Mass General Research Institute, Harvard Medical School, Boston, Massachusetts, USA.

Yorghos Tripodis (Y)

Department of Neurology, Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.

Jeffrey L Cummings (JL)

Department of Brain Health, Chambers-Grundy Center for Transformative Neuroscience, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, Nevada, USA.

Martha E Shenton (ME)

Departments of Psychiatry and Radiology, Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Robert A Stern (RA)

Department of Neurology, Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.

Eric M Reiman (EM)

Banner Alzheimer's Institute and Arizona Alzheimer's Consortium, Phoenix, Arizona, USA.
University of Arizona, Arizona State University, Translational Genomics Research Institute, Phoenix, Arizona, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH